Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -38 million and -20 million yuan, representing a year-on-year reduction in losses of 71.44 million to 89.44 million yuan [3]. - The net profit after deducting non-recurring gains and losses is projected to be between -55 million and -29 million yuan, compared to -109.08 million yuan in the same period last year [5]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 9 million to 17 million yuan [9]. Business Strategy and Operations - The company is focusing on optimizing its business structure and enhancing integrated operations, particularly in medical testing and pathology diagnosis services [8]. - The company is shifting its operational goals from pure scale and revenue growth to a focus on profitability and healthy cash flow [9]. - The company is investing in digital transformation and optimizing its product and service structure to address challenges in business revenue [8]. Market Environment and Challenges - The overall operating environment is under pressure due to multiple factors, including medical insurance cost control and expanded centralized procurement, impacting revenue expectations [8]. - The company is actively following national policies to improve collection progress on accounts receivable, with some long-aged receivables showing better collection results [8]. Financial Reporting - The financial data in the earnings forecast is preliminary and has not been audited by the accounting firm [10]. - The detailed financial data for 2025 will be disclosed in the company's annual report [10].
兰卫医学(301060) - 2025 Q4 - 年度业绩预告